STADOL (butorphanol tartrate) by Bristol Myers Squibb is mechanism of action butorphanol is a partial opioid agonist at the mu opioid receptor and a full agonist at the kappa opioid receptor. Approved for pain severe enough to require an opioid analgesic, for which alternative treatments are inadequate. First approved in 1978.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
STADOL (butorphanol tartrate) is an injectable opioid analgesic approved in 1978 for severe pain management when alternative treatments are inadequate. It functions as a partial agonist at mu opioid receptors and full agonist at kappa receptors, providing analgesia through central nervous system mechanisms. The drug is administered via injection and is primarily used in acute care and perioperative settings.
Approaching loss of exclusivity with moderate competitive pressure (30/100); Bristol Myers Squibb likely consolidating brand maintenance teams as patent protection weakens.
Mechanism of Action Butorphanol is a partial opioid agonist at the mu opioid receptor and a full agonist at the kappa opioid receptor. The principal therapeutic action of butorphanol is analgesia. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions,…
Worked on STADOL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on STADOL offers limited career upside given LOE-approaching status and minimal linked job openings (0). Roles are defensive and focused on protecting installed base in anesthesia and acute care rather than growth-oriented commercial expansion. Bristol Myers Squibb likely maintains a small, efficient team managing this legacy injectable franchise.